Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 750

1.

Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.

Reeskamp LF, Kastelein JJP, Moriarty PM, Duell PB, Catapano AL, Santos RD, Ballantyne CM.

Atherosclerosis. 2018 Nov 10;280:109-117. doi: 10.1016/j.atherosclerosis.2018.11.017. [Epub ahead of print]

PMID:
30500603
2.

Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD.

Navaneethan SD, Akeroyd JM, Ramsey D, Ahmed ST, Mishra SR, Petersen LA, Muntner P, Ballantyne C, Winkelmayer WC, Ramanathan V, Virani SS.

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1842-1850. doi: 10.2215/CJN.03830318. Epub 2018 Nov 29.

PMID:
30498000
3.

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators.

N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812792. [Epub ahead of print]

PMID:
30415628
4.

Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders.

Ligthart S, Vaez A, Võsa U, Stathopoulou MG, de Vries PS, Prins BP, Van der Most PJ, Tanaka T, Naderi E, Rose LM, Wu Y, Karlsson R, Barbalic M, Lin H, Pool R, Zhu G, Macé A, Sidore C, Trompet S, Mangino M, Sabater-Lleal M, Kemp JP, Abbasi A, Kacprowski T, Verweij N, Smith AV, Huang T, Marzi C, Feitosa MF, Lohman KK, Kleber ME, Milaneschi Y, Mueller C, Huq M, Vlachopoulou E, Lyytikäinen LP, Oldmeadow C, Deelen J, Perola M, Zhao JH, Feenstra B; LifeLines Cohort Study, Amini M; CHARGE Inflammation Working Group, Lahti J, Schraut KE, Fornage M, Suktitipat B, Chen WM, Li X, Nutile T, Malerba G, Luan J, Bak T, Schork N, Del Greco M F, Thiering E, Mahajan A, Marioni RE, Mihailov E, Eriksson J, Ozel AB, Zhang W, Nethander M, Cheng YC, Aslibekyan S, Ang W, Gandin I, Yengo L, Portas L, Kooperberg C, Hofer E, Rajan KB, Schurmann C, den Hollander W, Ahluwalia TS, Zhao J, Draisma HHM, Ford I, Timpson N, Teumer A, Huang H, Wahl S, Liu Y, Huang J, Uh HW, Geller F, Joshi PK, Yanek LR, Trabetti E, Lehne B, Vozzi D, Verbanck M, Biino G, Saba Y, Meulenbelt I, O'Connell JR, Laakso M, Giulianini F, Magnusson PKE, Ballantyne CM, Hottenga JJ, Montgomery GW, Rivadineira F, Rueedi R, Steri M, Herzig KH, Stott DJ, Menni C, Frånberg M, St Pourcain B, Felix SB, Pers TH, Bakker SJL, Kraft P, Peters A, Vaidya D, Delgado G, Smit JH, Großmann V, Sinisalo J, Seppälä I, Williams SR, Holliday EG, Moed M, Langenberg C, Räikkönen K, Ding J, Campbell H, Sale MM, Chen YI, James AL, Ruggiero D, Soranzo N, Hartman CA, Smith EN, Berenson GS, Fuchsberger C, Hernandez D, Tiesler CMT, Giedraitis V, Liewald D, Fischer K, Mellström D, Larsson A, Wang Y, Scott WR, Lorentzon M, Beilby J, Ryan KA, Pennell CE, Vuckovic D, Balkau B, Concas MP, Schmidt R, Mendes de Leon CF, Bottinger EP, Kloppenburg M, Paternoster L, Boehnke M, Musk AW, Willemsen G, Evans DM, Madden PAF, Kähönen M, Kutalik Z, Zoledziewska M, Karhunen V, Kritchevsky SB, Sattar N, Lachance G, Clarke R, Harris TB, Raitakari OT, Attia JR, van Heemst D, Kajantie E, Sorice R, Gambaro G, Scott RA, Hicks AA, Ferrucci L, Standl M, Lindgren CM, Starr JM, Karlsson M, Lind L, Li JZ, Chambers JC, Mori TA, de Geus EJCN, Heath AC, Martin NG, Auvinen J, Buckley BM, de Craen AJM, Waldenberger M, Strauch K, Meitinger T, Scott RJ, McEvoy M, Beekman M, Bombieri C, Ridker PM, Mohlke KL, Pedersen NL, Morrison AC, Boomsma DI, Whitfield JB, Strachan DP, Hofman A, Vollenweider P, Cucca F, Jarvelin MR, Jukema JW, Spector TD, Hamsten A, Zeller T, Uitterlinden AG, Nauck M, Gudnason V, Qi L, Grallert H, Borecki IB, Rotter JI, März W, Wild PS, Lokki ML, Boyle M, Salomaa V, Melbye M, Eriksson JG, Wilson JF, Penninx BWJH, Becker DM, Worrall BB, Gibson G, Krauss RM, Ciullo M, Zaza G, Wareham NJ, Oldehinkel AJ, Palmer LJ, Murray SS, Pramstaller PP, Bandinelli S, Heinrich J, Ingelsson E, Deary IJ, Mägi R, Vandenput L, van der Harst P, Desch KC, Kooner JS, Ohlsson C, Hayward C, Lehtimäki T, Shuldiner AR, Arnett DK, Beilin LJ, Robino A, Froguel P, Pirastu M, Jess T, Koenig W, Loos RJF, Evans DA, Schmidt H, Smith GD, Slagboom PE, Eiriksdottir G, Morris AP, Psaty BM, Tracy RP, Nolte IM, Boerwinkle E, Visvikis-Siest S, Reiner AP, Gross M, Bis JC, Franke L, Franco OH, Benjamin EJ, Chasman DI, Dupuis J, Snieder H, Dehghan A, Alizadeh BZ.

Am J Hum Genet. 2018 Nov 1;103(5):691-706. doi: 10.1016/j.ajhg.2018.09.009.

5.

Effect of Evolocumab on Coronary Plaque Composition.

Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE.

J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078.

PMID:
30336824
6.

Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.

Saeed A, Virani SS, Jones PH, Ballantyne CM, Nambi V.

J Clin Lipidol. 2018 Sep - Oct;12(5):1141-1145. doi: 10.1016/j.jacl.2018.05.017. Epub 2018 Jun 1.

PMID:
30318064
7.

Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.

Ballantyne CM, Bhatt DL, Cannon CP, Fazio S, Sabatine MS.

Am J Cardiol. 2018 Aug 16. pii: S0002-9149(18)31653-9. doi: 10.1016/j.amjcard.2018.08.020. [Epub ahead of print]

PMID:
30301542
8.

Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.

Roetker NS, MacLehose RF, Hoogeveen RC, Ballantyne CM, Basu S, Cushman M, Folsom AR.

Thromb Haemost. 2018 Nov;118(11):1940-1950. doi: 10.1055/s-0038-1673613. Epub 2018 Oct 8.

PMID:
30296818
9.

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).

Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ.

Eur Heart J. 2018 Oct 7;39(38):3499-3507. doi: 10.1093/eurheartj/ehy310.

PMID:
30165610
10.

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.

Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE.

Clin Cardiol. 2018 Oct;41(10):1281-1288. doi: 10.1002/clc.23055. Epub 2018 Sep 28. Review.

11.

Are All Benefits and Harms Equal?

Saeed A, Virani SS, Ballantyne CM, Taylor AA, Nambi V.

J Am Coll Cardiol. 2018 Aug 14;72(7):819-820. doi: 10.1016/j.jacc.2018.05.055. No abstract available.

PMID:
30092962
12.

Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study.

Warren B, Lee AK, Ballantyne CM, Hoogeveen RC, Pankow JS, Grams M, Köttgen A, Selvin E.

Clin Chem. 2018 Oct;64(10):1536-1537. doi: 10.1373/clinchem.2018.291773. Epub 2018 Aug 7. No abstract available.

PMID:
30087139
13.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, Baum SJ, Bourbon M, Carrié A, Cuchel M, de Ferranti SD, Defesche JC, Freiberger T, Hershberger RE, Hovingh GK, Karayan L, Kastelein JJP, Kindt I, Lane SR, Leigh SE, Linton MF, Mata P, Neal WA, Nordestgaard BG, Santos RD, Harada-Shiba M, Sijbrands EJ, Stitziel NO, Yamashita S, Wilemon KA, Ledbetter DH, Rader DJ; Convened by the Familial Hypercholesterolemia Foundation.

J Am Coll Cardiol. 2018 Aug 7;72(6):662-680. doi: 10.1016/j.jacc.2018.05.044. Review.

PMID:
30071997
14.

Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial.

Nicholls SJ, Puri R, Ballantyne CM, Jukema JW, Kastelein JJP, Koenig W, Wright RS, Kallend D, Wijngaard P, Borgman M, Wolski K, Nissen SE.

JAMA Cardiol. 2018 Sep 1;3(9):806-814. doi: 10.1001/jamacardio.2018.2112.

PMID:
30046837
15.

Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism.

Folsom AR, Lutsey PL, Heckbert SR, Poudel K, Basu S, Hoogeveen RC, Cushman M, Ballantyne CM.

J Thromb Haemost. 2018 Oct;16(10):1964-1972. doi: 10.1111/jth.14241. Epub 2018 Aug 11.

PMID:
30007116
16.

Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease.

Saeed A, Feofanova EV, Yu B, Sun W, Virani SS, Nambi V, Coresh J, Guild CS, Boerwinkle E, Ballantyne CM, Hoogeveen RC.

J Am Coll Cardiol. 2018 Jul 10;72(2):156-169. doi: 10.1016/j.jacc.2018.04.050.

PMID:
29976289
17.

Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease.

Faza NN, Akeroyd JM, Ramsey DJ, Shah T, Nasir K, Deswal A, Ballantyne CM, Petersen LA, Virani SS.

JAAPA. 2018 Jul;31(7):39-45. doi: 10.1097/01.JAA.0000534983.61613.91.

PMID:
29957606
18.

Correction to: Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions.

Saeed A, Dabhadkar K, Virani SS, Jones PH, Ballantyne CM, Nambi V.

Curr Atheroscler Rep. 2018 Jun 19;20(9):42. doi: 10.1007/s11883-018-0743-9.

PMID:
29915890
19.

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.

Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA.

Atherosclerosis. 2018 Oct;277:195-203. doi: 10.1016/j.atherosclerosis.2018.06.002. Epub 2018 Jun 12.

20.

Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity.

Wu J, Wu H, An J, Ballantyne CM, Cyster JG.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):6786-6791. doi: 10.1073/pnas.1805542115. Epub 2018 Jun 11.

PMID:
29891680
21.

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.

Basra SS, Wang TY, Simon DN, Chiswell K, Virani SS, Alam M, Nambi V, Denktas AE, Deswal A, Bozkurt B, Ballantyne CM, Peterson ED, Jneid H.

J Am Heart Assoc. 2018 Jun 9;7(12). pii: e008125. doi: 10.1161/JAHA.117.008125.

22.

Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study.

Oyenuga A, Folsom AR, Fashanu O, Aguilar D, Ballantyne CM.

Angiology. 2018 Jan 1:3319718780772. doi: 10.1177/0003319718780772. [Epub ahead of print]

PMID:
29879846
23.

Discovery, fine-mapping, and conditional analyses of genetic variants associated with C-reactive protein in multiethnic populations using the Metabochip in the Population Architecture using Genomics and Epidemiology (PAGE) study.

Kocarnik JM, Richard M, Graff M, Haessler J, Bien S, Carlson C, Carty CL, Reiner AP, Avery CL, Ballantyne CM, LaCroix AZ, Assimes TL, Barbalic M, Pankratz N, Tang W, Tao R, Chen D, Talavera GA, Daviglus ML, Chirinos-Medina DA, Pereira R, Nishimura K, Bužková P, Best LG, Ambite JL, Cheng I, Crawford DC, Hindorff LA, Fornage M, Heiss G, North KE, Haiman CA, Peters U, Le Marchand L, Kooperberg C.

Hum Mol Genet. 2018 Aug 15;27(16):2940-2953. doi: 10.1093/hmg/ddy211.

PMID:
29878111
24.

Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions.

Saeed A, Dabhadkar K, Virani SS, Jones PH, Ballantyne CM, Nambi V.

Curr Atheroscler Rep. 2018 May 21;20(7):35. doi: 10.1007/s11883-018-0735-9. Review. Erratum in: Curr Atheroscler Rep. 2018 Jun 19;20(9):42.

PMID:
29781057
25.

Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study.

Ding N, Kwak L, Ballew SH, Jaar B, Hoogeveen RC, Ballantyne CM, Sharrett AR, Folsom AR, Heiss G, Salameh M, Coresh J, Hirsch AT, Selvin E, Matsushita K.

Atherosclerosis. 2018 Jul;274:86-93. doi: 10.1016/j.atherosclerosis.2018.04.042. Epub 2018 Apr 30.

PMID:
29753232
26.

Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.

Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM.

Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e004652. doi: 10.1161/CIRCOUTCOMES.118.004652.

PMID:
29748356
27.

Orthostatic Hypotension and Risk of Clinical and Subclinical Cardiovascular Disease in Middle-Aged Adults.

Juraschek SP, Daya N, Appel LJ, Miller ER 3rd, McEvoy JW, Matsushita K, Ballantyne CM, Selvin E.

J Am Heart Assoc. 2018 May 7;7(10). pii: e008884. doi: 10.1161/JAHA.118.008884.

28.

The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study.

Walker KA, Windham BG, Power MC, Hoogeveen RC, Folsom AR, Ballantyne CM, Knopman DS, Selvin E, Jack CR Jr, Gottesman RF.

Neurobiol Aging. 2018 Aug;68:26-33. doi: 10.1016/j.neurobiolaging.2018.03.031. Epub 2018 Apr 4.

PMID:
29702373
29.

Bempedoic Acid (ETC-1002): A Current Review.

Saeed A, Ballantyne CM.

Cardiol Clin. 2018 May;36(2):257-264. doi: 10.1016/j.ccl.2017.12.007. Epub 2018 Feb 21. Review.

PMID:
29609755
30.

Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs.

McBride CL, Akeroyd JM, Ramsey DJ, Nambi V, Nasir K, Michos ED, Bush RL, Jneid H, Morris PB, Bittner VA, Ballantyne CM, Petersen LA, Virani SS.

Vasc Med. 2018 Jun;23(3):232-240. doi: 10.1177/1358863X18758914. Epub 2018 Mar 30.

PMID:
29600737
31.

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.

Brinton EA, Ballantyne CM, Guyton JR, Philip S, Doyle RT Jr, Juliano RA, Mosca L.

J Womens Health (Larchmt). 2018 Sep;27(9):1170-1176. doi: 10.1089/jwh.2017.6757. Epub 2018 Mar 27.

32.

High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study.

Matsushita K, Kwak L, Yang C, Pang Y, Ballew SH, Sang Y, Hoogeveen RC, Jaar BG, Selvin E, Ballantyne CM, Sharrett AR, Folsom AR, Heiss G, Coresh J, Hirsch AT.

Eur Heart J. 2018 Jul 1;39(25):2412-2419. doi: 10.1093/eurheartj/ehy106.

PMID:
29579246
33.

Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults.

Saeed A, Nambi V, Sun W, Virani SS, Taffet GE, Deswal A, Selvin E, Matsushita K, Wagenknecht LE, Hoogeveen R, Coresh J, de Lemos JA, Ballantyne CM.

J Am Coll Cardiol. 2018 Jun 5;71(22):2527-2536. doi: 10.1016/j.jacc.2018.02.050. Epub 2018 Mar 10.

PMID:
29535064
34.

Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study).

Tibuakuu M, Kianoush S, DeFilippis AP, McEvoy JW, Zhao D, Guallar E, Ballantyne CM, Hoogeveen RC, Blaha MJ, Michos ED.

Am J Cardiol. 2018 May 1;121(9):1056-1064. doi: 10.1016/j.amjcard.2018.01.020. Epub 2018 Feb 6.

PMID:
29525060
35.

Patient-Specific Flow Descriptors and Normalized wall index in Peripheral Artery Disease: a Preliminary Study.

Singh J, Brunner G, Morrisett JD, Ballantyne CM, Lumsden AB, Shah DJ, Decuzzi P.

Comput Methods Biomech Biomed Eng Imaging Vis. 2018;6(2):119-127. doi: 10.1080/21681163.2016.1184589. Epub 2016 Oct 12.

PMID:
29503774
36.

Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).

McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH.

Am J Cardiol. 2018 Apr 15;121(8):940-948. doi: 10.1016/j.amjcard.2017.12.040. Epub 2018 Feb 2.

37.

Improving Outcomes After Myocardial Infarction in the US Population.

Kayani WT, Ballantyne CM.

J Am Heart Assoc. 2018 Feb 17;7(4). pii: e008407. doi: 10.1161/JAHA.117.008407. No abstract available.

38.

Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts.

Garg PK, Bartz TM, Norby FL, Jorgensen NW, McClelland RL, Ballantyne CM, Chen LY, Gottdiener JS, Greenland P, Hoogeveen R, Jenny NS, Kizer JR, Rosenson RS, Soliman EZ, Cushman M, Alonso A, Heckbert SR.

Am Heart J. 2018 Mar;197:62-69. doi: 10.1016/j.ahj.2017.11.010. Epub 2017 Dec 5.

PMID:
29447785
39.

Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: ARIC Study.

Florido R, Kwak L, Lazo M, Nambi V, Ahmed HM, Hegde SM, Gerstenblith G, Blumenthal RS, Ballantyne CM, Selvin E, Folsom AR, Coresh J, Ndumele CE.

Circulation. 2018 May 15;137(20):2142-2151. doi: 10.1161/CIRCULATIONAHA.117.030226. Epub 2018 Jan 31.

PMID:
29386202
40.

Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study.

Vazir A, Claggett B, Cheng S, Skali H, Shah A, Agulair D, Ballantyne CM, Vardeny O, Solomon SD.

JAMA Cardiol. 2018 Mar 1;3(3):200-206. doi: 10.1001/jamacardio.2017.4974.

PMID:
29365021
41.

Galectin-3 and the incidence of abdominal aortic aneurysm: the atherosclerosis risk in communities (ARIC) study.

Fashanu OE, Folsom AR, Oyenuga A, Ballantyne CM, Lutsey PL, Tang W.

Am J Cardiovasc Dis. 2017 Dec 20;7(6):114-121. eCollection 2017.

42.

Prevention of "Failure": Is It a Failure of Prevention?

Nambi V, Deswal A, Ballantyne CM.

Circulation. 2018 Jan 9;137(2):106-108. doi: 10.1161/CIRCULATIONAHA.117.030645. No abstract available.

PMID:
29311345
43.

Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study).

Fretz A, McEvoy JW, Rebholz CM, Ndumele CE, Florido R, Hoogeveen RC, Ballantyne CM, Selvin E.

Am J Cardiol. 2018 Feb 15;121(4):430-436. doi: 10.1016/j.amjcard.2017.11.017. Epub 2017 Nov 24.

PMID:
29268937
44.

Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study.

Aronis KN, Zhao D, Hoogeveen RC, Alonso A, Ballantyne CM, Guallar E, Jones SR, Martin SS, Nazarian S, Steffen BT, Virani SS, Michos ED.

J Am Heart Assoc. 2017 Dec 15;6(12). pii: e007372. doi: 10.1161/JAHA.117.007372.

45.

SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study.

Vart P, Matsushita K, Rawlings AM, Selvin E, Crews DC, Ndumele CE, Ballantyne CM, Heiss G, Kucharska-Newton A, Szklo M, Coresh J.

Am J Prev Med. 2018 Feb;54(2):229-236. doi: 10.1016/j.amepre.2017.10.014. Epub 2017 Dec 11.

PMID:
29241718
46.

Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study.

Kubota Y, Folsom AR, Ballantyne CM, Tang W.

Atherosclerosis. 2018 Jan;268:63-67. doi: 10.1016/j.atherosclerosis.2017.10.017. Epub 2017 Nov 26.

PMID:
29182987
47.

Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC).

Garg PK, Norby FL, Polfus LM, Boerwinkle E, Gibbs RA, Grove ML, Folsom AR, Garimella PS, Matsushita K, Hoogeveen RC, Ballantyne CM.

Atherosclerosis. 2018 Jan;268:12-18. doi: 10.1016/j.atherosclerosis.2017.11.007. Epub 2017 Nov 14.

PMID:
29169030
48.

The I in autism: Severity and social functioning in autism are related to self-processing.

Gillespie-Smith K, Ballantyne C, Branigan HP, Turk DJ, Cunningham SJ.

Br J Dev Psychol. 2018 Mar;36(1):127-141. doi: 10.1111/bjdp.12219. Epub 2017 Nov 21.

PMID:
29159812
49.

Weight History and Subclinical Myocardial Damage.

Ndumele CE, Cobb L, Lazo M, Bello NA, Shah A, Nambi V, Blumenthal RS, Gerstenblith G, Solomon SD, Ballantyne CM, Selvin E, Coresh J.

Clin Chem. 2018 Jan;64(1):201-209. doi: 10.1373/clinchem.2017.282798. Epub 2017 Nov 20.

PMID:
29158254
50.

Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study.

Fashanu OE, Heckbert SR, Aguilar D, Jensen PN, Ballantyne CM, Basu S, Hoogeveen RC, deFilippi C, Cushman M, Folsom AR.

Res Pract Thromb Haemost. 2017 Oct;1(2):223-230. doi: 10.1002/rth2.12038. Epub 2017 Sep 4.

Supplemental Content

Loading ...
Support Center